The role of immunostimulatory nucleic acids in septic shock

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 1, 2011, Pages 1-23

  Bleiblo, Farag ^a   Michael, Paul ^a   Brabant, Danielle ^a   Ramana, Chilakamarti V ^b   Tai, T C ^a   Saleh, Mazen ^a   Parrillo, Joseph E ^c   Kumar, Anand ^d   Kumar, Aseem ^a  

^a Biomolecular Sciences Programme   (Canada)

^b YALE UNIVERSITY   (United States)

^c Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Immunostimulatory nucleic acid; Sepsis; Septic shock; Signaling networks; Therapy

Indexed keywords

BACTERIAL DNA; BACTERIAL RNA; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NUCLEIC ACID; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; RIG I LIKE RECEPTOR; RNA HELICASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEART MUSCLE CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PATHOGENESIS; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 84863032667     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (216)

1. Kumar A, Krieger A, Symeoneides S, Kumar A and Parrillo JE. Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth 2001; 15: 485-511.
2. Kumar A, Paladugu B, Mensing J, Kumar A and Parrillo JE. Nitric oxide-dependent and - independent mechanisms are involved in TNF- alpha -induced depression of cardiac myocyte contractility. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1900-6.
3. Kumar A, Kumar A, Paladugu B, Mensing J and Parrillo JE. Transforming growth factorbeta1 blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-alpha, interleukin-1beta, and human septic shock serum. Crit Care Med 2007; 35: 358-364.
4. Goldfarb RD and Parrillo JE. Complement. Crit Care Med 2005; 33: S482-4.
5. Pinheiro da Silva F and Nizet V. Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection. Apoptosis 2009; 14: 509-521.
6. Sriskandan S and Altmann DM. The immunology of sepsis. J Pathol 2008; 214: 211-223.
7. Kumar A, Kumar A, Michael P, Brabant D, Parissenti AM, Ramana CV, Xu X and Parrillo JE. Human serum from patients with septic shock activates transcription factors STAT1, IRF1, and NF-kappaB and induces apoptosis in human cardiac myocytes. J Biol Chem 2005; 280: 42619-42626.
8. Brabant D, Michael P, Bleiblo F, Saleh M, Narain R, Tai TC, Ramana CV, Parrillo JE, Kumar A and Kumar A. Septic sera induces apoptosis and DNA fragmentation factor 40 activation in fibroblasts. Biochem Biophys Res Commun 2011; 412: 260-265.
9. Hussein S, Michael P, Brabant D, Omri A, Narain R, Passi K, Ramana CV, Parrillo JE, Kumar A, Parissenti A and Kumar A. Characterization of human septic sera induced gene expression modulation in human myocytes. Int J Clin Exp Med 2009; 2: 131-148.
10. Reddy RC, Chen GH, Tekchandani PK and Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 2001; 24: 273-287.
11. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170: 1435-1444.
12. Rittirsch D, Flierl MA and Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787.
13. Aird WC. Sepsis and coagulation. Crit Care Clin 2005; 21: 417-431.
14. Lupu F. Crossroads in Sepsis Research Review Series Overview of the pathophysiology of sepsis. J Cell Mol Med 2008; 12: 1072-1073.
15. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
16. Castellheim A, Brekke OL, Espevik T, Harboe M and Mollnes TE. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 2009; 69: 479-491.
17. Akira S, Uematsu S and Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
18. Takeuchi O and Akira S. Signaling pathways activated by microorganisms. Current opinion in cell biology 2007; 19: 185-91.
19. Bowie AG and Fitzgerald KA. RIG-I: triing to discriminate between self and non-self RNA. Trends in immunology 2007; 28: 147-50.
20. Hornung V, Barchet W, Schlee M and Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol 2008; (183): 71-86.
21. Akira S and Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
22. Alexopoulou L and Kontoyiannis D. Contribution of microbial-associated molecules in innate mucosal responses. Cell Mol Life Sci 2005; 62: 1349-1358.
23. Janssens S and Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16: 637-646.
24. Bauer S, Pigisch S, Hangel D, Kaufmann A and Hamm S. Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology 2008; 213: 315-328.
25. Wagner H, Lipford GB and Hacker H. The role of immunostimulatory CpG-DNA in septic shock. Springer Semin Immunopathol 2000; 22: 167-171.
26. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
27. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H and Bauer S. Species-specific recognition of singlestranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
28. Koski GK, Kariko K, Xu S, Weissman D, Cohen PA and Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004; 172: 3989-3993.
29. Kariko K, Buckstein M, Ni H and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23: 165-175.
30. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR and Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171-1177.
31. Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N, Schreiber S, Voelkl A, Hartmann G and Endres S. Immunostimulatory RNA oligonucleotides trigger an antigenspecific cytotoxic T-cell and IgG2a response. Blood 2007; 109: 2953-2960.
32. Hamm S, Heit A, Koffler M, Huster KM, Akira S, Busch DH, Wagner H and Bauer S. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol 2007; 19: 297-304.
33. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP and Gasque P. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005; 280: 36342-36354.
34. Weighardt H and Holzmann B. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 2007; 212: 715-722.
35. Ishii KJ, Koyama S, Nakagawa A, Coban C and Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008; 3: 352-363.
36. Inohara, Chamaillard, McDonald C and Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74: 355-383.
37. Meylan E and Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006; 22: 561-569.
38. Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P, Bertin J, Coyle A, Grant EP, Akira S and Nunez G. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440: 233-236.
39. Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, Franchi L, Taraporewala ZF, Miller D, Patton JT, Inohara N and Nunez G. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006; 281: 36560-36568.
40. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ and Tschopp J. The in-flammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103-107.
41. Wu S and Kaufman RJ. A model for the double -stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J Biol Chem 1997; 272: 1291-1296.
42. Nallagatla SR, Hwang J, Toroney R, Zheng X, Cameron CE and Bevilacqua PC 5'- triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 2007; 318: 1455-1458.
43. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis S.C, Matsuura Y, Fujita T and Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-105.
44. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS and Colonna M. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 2006; 103: 8459-8464.
45. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S and Hartmann G. 5'- Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994-997.
46. Williams BRG. The role of the dsRNA-activated kinase, PKR, in signal transduction. Semin Virol 1995; 6: 191-202.
47. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
48. Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA and Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res 2004; 10: 247-251.
49. Lotze MT, Deisseroth A and Rubartelli A. Damage associated molecular pattern molecules. Clin Immunol 2007; 124: 1-4.
50. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T and Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955-962.
51. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
52. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D and Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A 1998; 95: 12631-12636.
53. Stacey KJ, Sweet MJ and Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-2122.
54. Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG and Walsh DS. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods 2001; 247: 83-94.
55. Hartmann G and Krieg AM. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther 1999; 6: 893-903.
56. Sweet MJ, Stacey KJ, Kakuda DK, Markovich D and Hume DA. IFN-gamma primes macrophage responses to bacterial DNA. J Interferon Cytokine Res 1998; 18: 263-271.
57. Cowdery JS, Boerth NJ, Norian LA, Myung PS and Koretzky GA. Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide. J Immunol 1999; 162: 6770-6775.
58. Kobayashi H, Horner AA, Takabayashi K, Nguyen MD, Huang E, Cinman N and Raz E. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol 1999; 198: 69-75.
59. Yi AK, Hornbeck P, Lafrenz DE and Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 1996; 157: 4918-4925.
60. Bendigs S, Salzer U, Lipford GB, Wagner H and Heeg K. CpG-oligodeoxynucleotides costimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999; 29: 1209-1218.
61. Sun S, Zhang X, Tough DF and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-2342.
62. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM and Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-3037.
63. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F and Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
64. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW and Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-2054.
65. Kadowaki N, Antonenko S and Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166: 2291-2295.
66. Hartmann G, Weiner GJ and Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999; 96: 9305-9310.
67. Shimada S, Yano O and Tokunaga T. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 1986; 77: 808-816.
68. Ballas ZK, Rasmussen WL and Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-1845.
69. Cowdery JS, Chace JH, Yi AK and Krieg AM. Bacterial DNA induces NK cells to produce IFN -gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996; 156: 4570-4575.
70. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE, Al-Shamkhani A, Flavell R, Borrow P and Reis e Sousa C. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003; 424: 324-328.
71. Alexopoulou L, Holt AC, Medzhitov R and Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
72. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA and Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 2004; 101: 3516-3521.
73. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E and Zitvogel L. Denritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-411.
74. Rouas R, Lewalle P, Ouriaghli F, Nowak B, Duvillier H and Martiat P. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol 2004; 16: 767-773.
75. Salem ML, Kadima AN, Cole DJ and Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005; 28: 220-228.
76. Burkett PR, Koka R, Chien M, Chai S, Chan F, Ma A and Boone DL. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. Proc Natl Acad Sci U S A 2003; 100: 4724-4729.
77. Wang L, Smith D, Bot S, Dellamary L, Bloom A and Bot A. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002; 110: 1175-1184.
78. Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF, Sullivan T and Agrawal S. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci U S A 2007; 104: 13750-13755.
79. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, Jung G, Rammensee HG and Pascolo S. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004; 34: 537-547.
80. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, Weller M and Pascolo S. Therapeutic anti-tumor immunity triggered by injections of immunostimulating singlestranded RNA. Eur J Immunol 2006; 36: 2807-2816.
81. Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM and Ishii KJ. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol 2005; 174: 2273-2279.
82. Hashimoto C, Hudson KL and Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52: 269-279.
83. Lemaitre B, Nicolas E, Michaut L, Reichhart JM and Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-983.
84. Rock FL, Hardiman G, Timans JC, Kastelein RA and Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998; 95: 588-593.
85. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
86. Medzhitov R, Preston-Hurlburt P and Janeway CA,Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
87. Kawai T and Akira S. TLR signaling. Semin Immunol 2007; 19: 24-32.
88. Takeda K and Akira S. Microbial recognition by Toll-like receptors. J Dermatol Sci 2004; 34: 73-82.
89. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ and Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75: 10730-10737.
90. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM and Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103.
91. Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint Girons I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, Underhill DM, Kirschning CJ, Wagner H, Aderem A, Tobias PS and Ulevitch RJ. Leptospiral lipopolysaccharide activates cells through a TLR2- dependent mechanism. Nat Immunol 2001; 2: 346-352.
92. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K and Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933-940.
93. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL and Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-14.
94. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E and Flavell RA. Hyporesponsiveness to vacciation with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002; 8: 878-884.
95. Philpott DJ and Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004; 41: 1099-1108.
96. Albiger B, Dahlberg S, Henriques-Normark B and Normark S. Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J Intern Med 2007; 261: 511-528.
97. Kawai T and Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825.
98. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K and Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643.
99. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K and Akira S. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329.
100. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K and Akira S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88- independent signaling pathway. Nat Immunol 2003; 4: 1144-1150.
101. Deane JA and Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol 2006; 177: 6573-6578.
102. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S and Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000; 192: 595-600.
103. Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, Suter M and Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci U S A 2004; 101: 11416-11421.
104. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela MM, Akira S, Yokoyama WM and Colonna M. TLR9- dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21: 107-119.
105. Lund J, Sato A, Akira S, Medzhitov R and Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-520.
106. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
107. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM and Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-1968.
108. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-198.
109. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H and Lipford GB. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98: 9237-9242.
110. Sester DP, Naik S, Beasley SJ, Hume DA and Stacey KJ. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol 2000; 165: 4165-4173.
111. Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, Bauer S, Hochrein H and Wagner H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9- dependent and -independent pathways. J Immunol 2005; 174: 6129-6136.
112. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A and Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatinimmunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
113. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT and Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-417.
114. Fields ML, Metzgar MH, Hondowicz BD, Kang SA, Alexander ST, Hazard KD, Hsu AC, Du YZ, Prak EL, Monestier M and Erikson J. Exogenous and endogenous TLR ligands activate anti-chromatin and polyreactive B cells. J Immunol 2006; 176: 6491-6502.
115. Haas T, Metzger J, Schmitz F, Heit A, Muller T, Latz E and Wagner H. The DNA sugar back-bone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008; 28: 315-323.
116. Matsumoto J, Ohshima T, Isono O and Shimotohno K. HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene 2005; 24: 1001-1010.
117. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A and Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171: 3154-3162.
118. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ and Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004; 173: 1179-1183.
119. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A and Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004; 16: 1143-1154.
120. Nishiya T, Kajita E, Miwa S and Defranco AL. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005; 280: 37107-37117.
121. Barton GM, Kagan JC and Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7: 49-56.
122. Crozat K and Beutler B. TLR7: A new sensor of viral infection. Proc Natl Acad Sci U S A 2004; 101: 6835-6836.
123. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y and Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 2006; 36: 3256-3267.
124. Rozenski J, Crain PF and McCloskey JA. The RNA Modification Database: 1999 update. Nucleic Acids Res 1999; 27: 196-197.
125. Bieger CD and Nierlich DP. Distribution of 5 triphosphate termini on the mRNA of Escherichia coli. J Bacteriol 1989; 171: 141-147.
126. Maquat LE and Carmichael GG. Quality control of mRNA function. Cell 2001; 104: 173-176.
127. Doma MK and Parker R. RNA quality control in eukaryotes. Cell 2007; 131: 660-668.
128. Grosjean H, Björk G and Maden BEH. Nucleotide modification and base conversion of RNA: Summary and outlook. Biochimie 1995; 77: 3-6.
129. Margulis L and Chapman MJ. Endosymbioses: cyclical and permanent in evolution. Trends Microbiol 1998; 6: 342-5; discussion 345-6.
130. Kanneganti TD, Lamkanfi M and Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27: 549-559.
131. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, Jagirdar R, Inohara N, Vandenabeele P, Bertin J, Coyle A, Grant EP and Nunez G. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 2006; 7: 576-582.
132. Kufer TA and Sansonetti PJ. Sensing of bacteria: NOD a lonely job. Curr Opin Microbiol 2007; 10: 62-69.
133. Rietdijk ST, Burwell T, Bertin J and Coyle AJ. Sensing intracellular pathogens-NOD-like receptors. Curr Opin Pharmacol 2008; 8: 261-266.
134. Fritz JH, Ferrero RL, Philpott DJ and Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006; 7: 1250-1257.
135. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, Ogura Y, Kawasaki A, Fukase K, Kusumoto S, Valvano MA, Foster SJ, Mak TW, Nunez G and Inohara N. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4: 702-707.
136. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ and Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872.
137. Hasegawa M, Yang K, Hashimoto M, Park JH, Kim YG, Fujimoto Y, Nunez G, Fukase K and Inohara N. Differential release and distribution of Nod1 and Nod2 immunostimulatory molecules among bacterial species and environments. J Biol Chem 2006; 281: 29054-29063.
138. Inohara N and Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371-382.
139. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G and Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.
140. Opitz B, Puschel A, Schmeck B, Hocke AC, Rosseau S, Hammerschmidt S, Schumann RR, Suttorp N and Hippenstiel S. Nucleotidebinding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004; 279: 36426-36432.
141. Petrilli V, Dostert C, Muruve DA and Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-622.
142. Perregaux D and Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269: 15195-15203.
143. Martinon F, Petrilli V, Mayor A, Tardivel A and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
144. Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, Miller SI and Aderem A. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006; 7: 569-575.
145. Amer A, Franchi L, Kanneganti TD, Body-Malapel M, Ozoren N, Brady G, Meshinchi S, Jagirdar R, Gewirtz A, Akira S and Nunez G. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 2006; 281: 35217-35223.
146. Molofsky AB, Byrne BG, Whitfield NN, Madigan CA, Fuse ET, Tateda K and Swanson MS. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J Exp Med 2006; 203: 1093-1104.
147. Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG and Girardin SE. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol 2007; 29: 289-301.
148. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM and Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006; 281: 2005-2011.
149. Philpott DJ, Yamaoka S, Israel A and Sansonetti PJ. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharidedependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165: 903-914.
150. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ and Philpott DJ. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2001; 2: 736-742.
151. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, Medzhitov R and Flavell RA. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002; 416: 194-199.
152. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I and Reed JC. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 2007; 25: 713-724.
153. Yoneyama M and Fujita T. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity. Cytokine Growth Factor Rev 2007; 18: 545-551.
154. Sumpter R,Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM and Gale M,Jr. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79: 2689-2699.
155. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, M. G,Jr, Akira S, Yonehara S, Kato A and Fujita T. Shared and unique functions of the DExD/Hbox helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-8.
156. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M,Jr, Akira S, Yonehara S, Kato A and Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-2858.
157. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737.
158. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T and M. G,Jr. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 582-7.
159. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T and Gale M,Jr. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 2007; 104: 582-587.
160. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O and Akira S. Cell typespecific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
161. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S and Randall RE. The V proteins of paramyxoviruses bind the IFN- inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 2004; 101: 17264-17269.
162. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O and Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6: 981-988.
163. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R and Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172.
164. Yoneyama M and Fujita T. Function of RIG-I- like receptors in antiviral innate immunity. J Biol Chem 2007; 282: 15315-15318.
165. Seth RB, Sun L, Ea CK and Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122: 669-682.
166. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z and Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19: 727-740.
167. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM and Gale M,Jr. Viral and therapeutic control of IFN- beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103: 6001-6006.
168. Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E and Hiscott J. Dissociation of a MAVS/IPS-1/ VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 2006; 80: 6072-6083.
169. Li XD, Sun L, Seth RB, Pineda G and Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 2005; 102: 17717-17722.
170. Saha SK, Pietras EM, He JQ, Kang JR, Liu SY, Oganesyan G, Shahangian A, Zarnegar B, Shiba TL, Wang Y and Cheng G. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J 2006; 25: 3257-3263.
171. Perry AK, Chow EK, Goodnough JB, Yeh WC and Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004; 199: 1651-1658.
172. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, Kawai T, Hoshino K, Takeda K and Akira S. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199: 1641-1650.
173. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A and Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007; 315: 1274-1278.
174. Guo B and Cheng G. Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. J Biol Chem 2007; 282: 11817-11826.
175. Sasai M, Shingai M, Funami K, Yoneyama M, Fujita T, Matsumoto M and Seya T. NAK- associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. J Immunol 2006; 177: 8676-8683.
176. Ryzhakov G and Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J 2007; 26: 3180-3190.
177. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N and Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777.
178. Takahashi K, Kawai T, Kumar H, Sato S, Yonehara S and Akira S. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J Immunol 2006; 176: 4520-4524.
179. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F and Reis e Sousa C. RIG-I-mediated antiviral responses to singlestranded RNA bearing 5'-phosphates. Science 2006; 314: 997-1001.
180. Fredericksen BL, Keller BC, Fornek J, Katze MG and Gale M,Jr. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008; 82: 609-616.
181. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, Akira S, Gill MA, Garcia-Sastre A, Katze MG and Gale M,Jr. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 2008; 82: 335-345.
182. Yoneyama M, Onomoto K and Fujita T. Cytoplasmic recognition of RNA. Adv Drug Deliv Rev 2008; 60: 841-846.
183. Dostert C, Meylan E and Tschopp J. Intracellular pattern-recognition receptors. Adv Drug Deliv Rev 2008; 60: 830-840.
184. Horn DL, Morrison DC, Opal SM, Silverstein R, Visvanathan K and Zabriskie JB. What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis 2000; 31: 851-858.
185. Sparwasser T, Miethke T, Lipford G, Borschert K, Hacker H, Heeg K and Wagner H. Bacterial DNA causes septic shock. Nature 1997; 386: 336-337.
186. Nansen A and Randrup Thomsen A. Viral infection causes rapid sensitization to lipopolysac-charide: central role of IFN-alpha beta. J Immunol 2001; 166: 982-988.
187. Doughty LA, Carlton S, Galen B, Cooma-Ramberan I, Chung CS and Ayala A. Activation of common antiviral pathways can potentiate inflammatory responses to septic shock. Shock 2006; 26: 187-194.
188. Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R and Morrison DC. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 1999; 163: 4095-4099.
189. Gao JJ, Xue Q, Papasian CJ and Morrison DC. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 2001; 166: 6855-6860.
190. Jiang W, Bell CW and Pisetsky DS. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol 2007; 178: 6495-6503.
191. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S and Sugden PH. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 2007; 212: 311-322.
192. Court O, Kumar A, Parrillo JE and Kumar A. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6: 500-508.
193. de Kleijn D and Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60: 58-67.
194. Frantz S, Ertl G and Bauersachs J. Mechanisms of disease: Toll-like receptors in cardio-vascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444-454.
195. Pure E and Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med 2001; 7: 213-221.
196. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL and Mochizuki H. Role of Toll-like receptors in the development of sepsis. Shock 2008; 29: 315-321.
197. Armstrong L, Medford AR, Hunter KJ, Uppington KM and Millar AB. Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 2004; 136: 312-319.
198. Tsujimoto H, Ono S, Majima T, Kawarabayashi N, Takayama E, Kinoshita M, Seki S, Hiraide H, Moldawer LL and Mochizuki H. Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 2005; 23: 39-44.
199. Williams DL, Ha T, Li C, Kalbfleisch JH, Schweitzer J, Vogt W and Browder IW. Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003; 31: 1808-1818.
200. Salomao R, Brunialti MK, Gomes NE, Mendes ME, Diaz RS, Komninakis S, Machado FR, da Silva ID and Rigato O. Toll-like receptor pathway signaling is differently regulated in neutrophils and peripheral mononuclear cells of patients with sepsis, severe sepsis, and septic shock. Crit Care Med 2009; 37: 132-139.
201. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104: 271-280.
202. Boyd JH, Mathur S, Wang Y, Bateman RM and Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflamma tory response. Cardiovasc Res 2006; 72: 384-393.
203. Zhu X, Bagchi A, Zhao H, Kirschning CJ, Hajjar RJ, Chao W, Hellman J and Schmidt U. Toll-like receptor 2 activation by bacterial peptidogly-can-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med 2007; 35: 886-892.
204. Mitchell JA, Ryffel B, Quesniaux VF, Cartwright N and Paul-Clark M. Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans 2007; 35: 1449-1452.
205. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M and Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000; 275: 11058-11063.
206. Jimenez R, Belcher E, Sriskandan S, Lucas R, McMaster S, Vojnovic I, Warner TD and Mitchell JA. Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A 2005; 102: 4637-4642.
207. Cartwright N, McMaster SK, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, Quesniaux VF, Evans TW and Mitchell JA. Elucidation of toll-like receptor and adapter protein signaling in vascular dysfunction induced by grampositive Staphylococcus aureus or gramnegative Escherichia coli. Shock 2007; 27: 40-47.
208. Paladugu B, Kumar A, Parrillo JE, Der S, Osman J, Mensing J, Falvo L, Xu X and Kumar A. Bacterial DNA and RNA induce rat cardiac myocyte contraction depression in vitro. Shock 2004; 21: 364-369.
209. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rudiger M, Boehm O, Fink K, Dreiner U, Grohe C, Hoeft A, Baumgarten G, Koch A, Zacharowski K and Meyer R. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res 2008; 78: 26-35.
210. Pisetsky DS. The antigenic properties of bacterial DNA in normal and aberrant immunity. Springer Semin Immunopathol 2000; 22: 153-166.
211. Wagner H and Bauer S. All is not Toll: new pathways in DNA recognition. J Exp Med 2006; 203: 265-268.
212. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S and Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202: 321-331.
213. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG and Moroy T. Features of systemic lupus erythematosus in Dnase1- deficient mice. Nat Genet 2000; 25: 177-181.
214. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S and Krieg AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575-1585.
215. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S and Krug A. U1 small nuclear ribonu-cleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107: 3229-3234.
216. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, Wortis HH, Kearney JF, Ucci AA and Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 2006; 25: 429-440